Abstract
Sulforaphene (SFE, 4-methylsufinyl-3-butenyl isothiocyanate) is a member of isothiocyanates, which is derived from radish seeds. It has shown that multiple isothiocyanates, such as sulforaphane, can effectively inhibit cancer cell proliferation in vitro and in vivo. However, it is still largely unknown if SFE could impact breast cancer. In this study, we investigated the anticancer effects of SFE on triple negative breast cancer (TNBC) via a series of in vitro and in vivo assays. We found that SFE can significantly inhibit cell proliferation in multiple TNBC cell lines through inducing G2/M phase arrest as well as cell apoptosis. Nude mice xenograft assays support the anti-TNBC role of SFE in vivo. Interestingly, SFE can repress expression of cyclinB1, Cdc2, and phosphorylated Cdc2, and, then, induced G2/M phase arrest of TNBC cells. To identify SFE target genes, we detected genome-wide gene expression changes through gene expression profiling and observed 27 upregulated and 18 downregulated genes in MDA-MB-453 cells treated with SFE. Among these genes, Egr1 was successfully validated as a consistently activated gene after SFE treatment in TNBC MDA-MB-453 and MDA-MB-436 cells. Egr1 overexpression inhibited proliferation of TNBC cells. However, Egr1 knockdown using siRNAs significantly promoted TNBC cell growth, indicating the tumor suppressor nature of Egr1. In sum, we for the first time found that SFE might be a potential anti-TNBC natural compound and its antiproliferation effects might be mediated by tumor suppressor Egr1.
Similar content being viewed by others
References
Siegel RL, Miller KD, Jemal A (2015) Cancer statistics, 2015. Cancer J Clin 65:5–29
Scalia-Wilbur J, Colins BL, Penson RT, Dizon DS (2016) Breast cancer risk assessment: moving beyond BRCA1 and 2. Semin Radiat Oncol 26:3–8
Brenton JD, Carey LA, Ahmed AA, Caldas C (2005) Molecular classification and molecular forecasting of breast cancer: ready for clinical application. J Clin Oncol 23:7350–7360
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. Cancer J Clin 61:69–90
Hsu YH, Yao J, Chan LC, Wu TJ, Hsu JL (2014) Definition of PKC-α, CDK6, and MET as therapeutic targets in triple-negative breast cancer. Cancer Res 74:4822–4835
D’Amato NC, Rogers TJ, Gordon MA, Greene LI (2015) A TDO2-AhR signaling axis facilitates anoikis resistance and metastasis in triple-negative breast cancer. Cancer Res 75:4651–4664
Witherby S, Rizack T, Sakr BJ, Legare RD, Sikov WM (2016) Advances in medical management of early stage and advanced breast cancer: 2015. Semin Radiat Oncol 26:59–70
Verhoeven DT, Goldbohm RA, van Poppel G, Verhagen H, van den Brandt PA (1996) Epidemiological studies on brassica vegetables and cancer risk. Cancer Epidemiol Biomark Prev 5:733–748
Kuang P, Song D, Yuan Q, Yi R, Lv X, Liang H (2013) Separation and purification of sulforaphene from radish seeds using macroporous resin and preparative high-performance liquid chromatography. Food Chem 136:342–347
Pocasap P, Weerapreeyakul N, Barusrux S (2013) Cancer preventive effect of Thai rat-tailed radish (Raphanus sativus L. var. caudatus Alef). J Funct Food 5:1372–1381
Papi A, Orlandi M, Bartolini G, Barillari J, Iori R, Paolini M, Ferroni F, Grazia Fumo M, Pedulli GF, Valgimigli L (2008) Cytotoxic and antioxidant activity of 4-methylthio-3-butenyl isothiocyanate from Raphanus sativus L. (Kaiware Daikon) sprouts. J Agric Food Chem 56:875–883
Nastruzzi C, Cortesi R, Esposito E, Menegatti E, Leoni O, Iori R, Palmieri S (2000) In vitro antiproliferative activity of isothiocyanates and nitriles generated by myrosinase-mediated hydrolysis of glucosinolates from seeds of cruciferous vegetables. J Agric Food Chem 48:3572–3575
Ambrosone CB, McCann SE, Freudenheim JL, Marshall JR, Zhang Y, Shields PG (2004) Breast cancer risk in premenopausal women is inversely associated with consumption of broccoli, a source of isothiocyanates, but is not modified by GST genotype. J Nutr 134:1134–1138
Fowke JH, Chung FL, Jin F, Qi D, Cai Q, Conaway C, Cheng JR, Shu XO, Gao YT, Zheng W (2003) Urinary isothiocyanate levels, brassica, and human breast cancer. Cancer Res 63:3980–3986
Terry P, Wolk A, Persson I, Magnusson C (2001) Brassica vegetables and breast cancer risk. J Am Med Assoc 285:2975–2977
Zhao C, Yue B, Liu H, Sun C, Li W, Qu X (2012) SL-01, an oral gemcitabine derivative, inhibited human cancer growth more potently than gemcitabine. Toxicol Appl Pharmacol 262:293–300
Bonnesen C, Eggleston IM, Hayes JD (2001) Dietary indoles and isothiocyanates that are generated from cruciferous vegetables can both stimulate apoptosis and confer protection against DNA damage in human colon cell lines. Cancer Res 61:6120–6130
Choi S, Lew KL, Xiao H, Herman-Antosiewicz A (2007) D, L-Sulforaphane-induced cell death in human prostate cancer cells is regulated by inhibitor of apoptosis family proteins and Apaf-1. Carcinogenesis 28:151–162
Gamet Payrastre L, Li P, Lumeau S, Cassar G, Dupont MA, Chevolleau S (2000) Sulforaphane, a naturally occurring isothiocyanate, induces cell cycle arrest and apoptosis in HT29 human colon cancer cells. Cancer Res 60:1426–1433
Hu K, Qi YJ, Zhao J, Jiang HF, Chen X, Ren J (2013) Synthesis and biological evaluation of sulforaphane derivatives as potential antitumor agents. Eur J Med Chem 64:529–539
Chang CC, Hung CM, Yang YR, Lee MJ, Hsu YC (2013) Sulforaphane induced cell cycle arrest in the G2/M phase via the blockade of cyclin B1/CDC2 in human ovarian cancer cells. J Ovarian Res 6:41
Gould KA, Tochacek M, Schaffer BS, Reindl TM, Murrin CR, Lachel CM, VanderWoude EA, Pennington KL, Flood LA, Bynote KK et al (2004) Genetic determination of susceptibility to estrogen-induced mammary cancer in the ACI rat: mapping of Emca1 and Emca2 to chromosomes 5 and 18. Genetics 168:2113–2125
Ruetz S, Fabbro D, Zimmermann J, Meyer T, Gray N (2003) Chemical and biological profile of dual Cdk1 and Cdk2 inhibitors. Curr Med Chem Anti 3:1–14
Stark GR, Taylor WR (2006) Control of the G2/M transition. Mol Biotechnol 32:227–248
Choi YH, Yoo YH (2012) Taxol-induced growth arrest and apoptosis is associated with the upregulation of the Cdk inhibitor, p21WAF1/CIP1, in human breast cancer cells. Oncol Rep 28:2163–2169
Han SJ, Conti M (2006) New pathways from PKA to the Cdc2/cyclin B complex in oocytes: wee1B as a potential PKA substrate. Cell Cycle 5:227–231
Milbrandt J (1987) A nerve growth factor-induced gene encodes a possible transcriptional regulatory factor. Science 238:797–799
Bhattacharyya S, Fang F, Tourtellotte W, Varga J (2013) Egr1: new conductor for the tissue repair orchestra directs harmony (regeneration) or cacophony (fibrosis). Am J Pathol 229:286–297
Rong Y, Hu F, Huang RP, Mackman N, Horowitz JM, Jensen RL et al (2006) Early growth response gene-1 regulates hypoxia-induced expression of tissue factor in glioblastoma multiforme through hypoxia-inducible factor-1 – independent mechanisms. Cancer Res 66:7067–7074
Thiel G, Cibelli G (2002) Regulation of life and death by the zinc finger transcription factor Egr1. J Cell Physiol 193:287–292
Redmond KL, Crawford NT, Farmer H, D’Costa ZC, O’Brien GJ, Buckley NE (2010) T-box 2 represses NDRG1 through an Egr1-dependent mechanism to drive the proliferation of breast cancer cells. Oncogene 29:3252–3262
Grant support
This work was supported by the National High-Tech Research and Development Program of China (2015AA020950); the Fundamental Research Funds for the Central Universities (YS1407); the open project of State Key Laboratory of Molecular Oncology (SKL-KF-2015-05); Program for Changjiang Scholars and Innovative Research Team in University (IRT13045); Innovation and Promotion Project of Beijing University of Chemical Technology.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no competing financial interests.
Additional information
Ming Yang, Wendi Teng and Yue Qu have contributed equally to this work.
Rights and permissions
About this article
Cite this article
Yang, M., Teng, W., Qu, Y. et al. Sulforaphene inhibits triple negative breast cancer through activating tumor suppressor Egr1 . Breast Cancer Res Treat 158, 277–286 (2016). https://doi.org/10.1007/s10549-016-3888-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-016-3888-7